Company Presentation

Cimeio is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with debilitating and life-threatening diseases. It’s proprietary technology platform – discovered in the labs of founder Prof. Dr. Lukas Jeker at the University of Basel – is based on novel protein variants, which when inserted into cells allow them to preserve function while resisting depletion by a precisely paired immunotherapy.